Press Releases Year: - Any -20192018 Items per page 102550 March 28, 2019 at 7:00 AM EDT Summary ToggleEntera Bio Announces 20-F Filing JERUSALEM , March 28, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that it has filed its Annual Report on Form 20-F for the year ended December 31, 2018 , with the U.S. Securities and Exchange Commission . A copy of the Annual Report available in the Investor Relations March 28, 2019 at 7:00 AM EDT Summary ToggleEntera Bio Reports 2018 Annual Financial Results and Operating Update Positive feedback and guidance from the US FDA regarding development plans for Oral PTH in osteoporosis Entered into research collaboration and license agreement with Amgen , potential for up to $270 million in milestone payments, Amgen’s exercise of options to select additional programs and March 27, 2019 at 11:02 AM EDT Summary ToggleEntera Bio to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Thursday, March 28 Conference Call Scheduled for 10am Eastern Time / 2pm Greenwich Mean Time JERUSALEM , March 27, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the fourth quarter and year ended December 31, 2018 before the market open on Thursday, March 7, 2019 at 7:00 AM EST Summary ToggleEntera Bio Announces a Transition in the Chief Financial Officer Position JERUSALEM , March 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that Mira Rosenzweig , Chief Financial Officer, will be leaving the Company in mid-April 2019 on amicable terms to pursue other professional opportunities closer to her home. Ms. January 31, 2019 at 8:00 AM EST Summary ToggleEntera Bio Announces Positive Feedback and Guidance from the US FDA Regarding its Development Plans for Oral PTH in Osteoporosis JERUSALEM , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the positive outcome of a pre-IND meeting held with the US Food and Drug Administration ( FDA ) to discuss the Company’s development plan for Oral PTH for the treatment of osteoporosis. January 22, 2019 at 8:00 AM EST Summary ToggleEntera Bio Reports Third Quarter 2018 Financial Results and Operating Update Entered into research collaboration and license agreement with Amgen , potential for up to $270 million in milestone payments, as well as royalties on commercial sales Met with FDA in late November 2018 to discuss clinical development plan for EB613 in the treatment of osteoporosis Reported January 10, 2019 at 7:00 AM EST Summary ToggleEntera Bio Appoints Gerald M. Ostrov to Board of Directors JERUSALEM , Jan. 10, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) announced today the appointment of Gerald M. Ostrov as a new independent director on its Board of Directors, effective immediately. “We are pleased to have Jerry join our Board of Directors. December 11, 2018 at 7:00 AM EST Summary ToggleEntera Bio and Amgen Enter Strategic Research Collaboration in Inflammatory Disease and Other Serious Illnesses Amgen will have the option to advance up to three large molecule programs using Entera’s oral delivery technology Entera will be eligible to receive up to $270 million in clinical and commercial milestone payments JERUSALEM , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. November 8, 2018 at 8:00 AM EST Summary ToggleEntera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism - - - Demonstrates positive results in three metabolic parameters in patients with hypoparathyroidism treated with Oral PTH (1-34) - - - Reports a significant decrease in 24-hour urinary calcium in hypoparathyroid patients treated with Oral PTH (1-34) - - - JERUSALEM, Israel , Nov. October 2, 2018 at 8:00 AM EDT Summary ToggleEntera Bio Appoints Two New External Independent Members to the Board of Directors JERUSALEM , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today the appointment of Faith L. Charles and Miranda J. Toledano to the company’s board of directors, effective immediately. The appointments of Ms. Charles and Ms. Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Next page Next Last page Last